top of page
Search

Illumina

  • Writer: Abacus Research
    Abacus Research
  • May 4, 2023
  • 1 min read

Illumina is facing many issues, including patent expirations, regulatory problems both in Europe and the US, a failed deal and increasing competition. Doesn't sound that attractive... however, the mess will get cleaned up over the next 12 months and Illumina will return to its core business, which is attractive, and just in front of a new product cycle.

In our upside scenario we estimate that the core ILMN could generate EPS of ~$10 sometime in 2026 versus consensus estimates of $5 in 2025.

  • The clean up: Regulators have ordered Illumina to divest Grail. Grail is a non profitable business. (Revenue $90-$110m, operating Loss: ~$670m.),

  • We expect Grail to be divested in 2023/24, as we sense a consensus among investors and probably the management that it got carried away in 2021. Involvement of an activist investor (Icahn) helps to hasten the divestment process.

  • Which will leave Core Illumina:

    • The key bet in ILMN is an instrument upgrade cycle and high elasticity of demand, which allows ILMN to grow revenue mid-teens in 2024/2025 with 25-28% operating margins.


Potential Upside: $350 (+64%)

Sensible Downside: $140(-35%)

 
 
 

Recent Posts

See All
Axon:

Axon is shifting from selling individual tools to providing an interconnected ecosystem. Hardware like TASERs and cameras now act as "data generators" that feed directly into high-margin software modu

 
 
 
C.H. Robinson

CHRW has been going through significant change, They are retaking market share. The new CEO has transformed the company by bringing in a lean / AI, that has helped CHRW to grow earnings despite strugg

 
 
 
Brookfield (BN):

We initially wrote up BN in Jan 2024, it has increased 70%, so why mention it again? Firstly, we think the fundamentals are as good now as they were 2 yrs ago, with a >15% IRR on offer. BN is not a we

 
 
 

Comments

bottom of page